ClinicalTrials.gov record
Terminated Phase 2Phase 3 Interventional

Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients

ClinicalTrials.gov ID: NCT04472728

Public ClinicalTrials.gov record NCT04472728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Adaptive Design Phase 2 to 3, Randomized, Double-blind, to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BIO101 in the Prevention of the Respiratory Deterioration in Hospitalized COVID-19 Patients

Study identification

NCT ID
NCT04472728
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Biophytis
Industry
Enrollment
238 participants

Conditions and interventions

Interventions

  • BIO101 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
45 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 25, 2020
Primary completion
Jun 5, 2022
Completion
Sep 29, 2022
Last update posted
May 14, 2023

2020 – 2022

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
Abrazo Health Phoenix Arizona 85015
University of California, Irvine Irvine California 92697
Barnum Medical Research, Inc. 1029 Keyser Ave Suite H Natchitoches Louisiana 71457
Beaumont Health Royal Oak Michigan 48073
United Health Services Hospitals Johnson City New York 13903
WellSpan Health York Pennsylvania 17403

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04472728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 14, 2023 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04472728 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →